Doctors at Boston’s Beth Israel share how CAR T cell therapy and other emerging immune therapies are delivering promising ...

Bristol Myers Squibb said the U.S. Food and Drug Administration has granted priority review to its application seeking approval of its iberdomide drug candidate in certain patients with the blood ...

Nocturnal symptoms and musculoskeletal pain are filtered through relapse fear, driving repetitive interpretation of ...

The next chapter in hematology is being written at City of Hope. For patients navigating blood cancers like leukemia, lymphoma or multiple myeloma, having access to specialized experts and the most ...

Hospitals are seeing success treating multiple myeloma with advanced therapies. Second autologous stem cell transplants, even ...

Global market grows at 6.3% CAGR through 2033 as demand rises for safer, targeted chemotherapy treatments worldwide.

Annual meeting moves to the New York Marriott Marquis on October 13-16, marking a new chapter and providing a refreshed ...

Johnson & Johnson recently reported real-world data showing that ERLEADA® without docetaxel was associated with a statistically significant 51% reduction in risk of death versus darolutamide in ...

Melissa L. Johnson, MD, is now chief scientific officer while retaining leadership of lung cancer research, and Erika P. Hamilton, MD, is now chief development officer, late phase, while remaining the ...

By: Dr. Amrit Kaur Kaler For patients diagnosed with blood cancers such as leukemia, lymphoma, and multiple myeloma, the journey can be overwhelming. Treatments are often intense, and the risk of ...

Our NAV-005 antagonist binds the immunosuppressive HIO-1 factor and blocks its ability to suppress mAb, TCE and ADC ...

Cancer survival is improving, but what about life after treatment? Doctors explain the hidden reproductive and hormonal impact of chemotherapy.